IPHYF News and Press, Innate Pharma From 03/21/24

Innate Pharma - Class A (IPHYF) is expected to report for quarter end 2023-12-31

2024-03-21 05:21:58 ET More on Innate Pharma Innate Pharma: Worth A Deeper Look FDA lifts partial clinical hold on Innate Pharma's lacutamab clinical program; leadership change Seeking Alpha’s Quant Rating on Innate Pharma Read the full article on Se...

Positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome presented at ASH Annual Meeting 2023; final data in mycosis fungoides to be shared at an upcoming medical congress Licensing of a fourth NK cell engager ANKET ® by Sanofi, triggering a €...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financia...

Phase 1/2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, from ANKET ® platform, for the treatment of CD20-expressing B-cell Non-Hodgkin's Lymphomas. Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: ...

IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IPH45, a differentiated topoisomerase I inhibitor ADC targeting Nectin-4, which is progressing towards the clinic Regulatory News: Innate...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below. Leerin...

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...

2024-01-11 08:42:53 ET Summary Innate Pharma is a European biotech specializing in the development of immunotherapeutics for various cancer types. Their most advanced projects focus on engaging and activating natural killer cells, with promising results in clinical trials. The...

2024-01-04 04:25:35 ET More on Innate Pharma: Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi Seeking Alpha’s Quant Rating on Innate Pharma For further details see: FDA lifts partial clinical hold on Innate Pharma's lacutamab c...